Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR

Journal of Molecular Diagnostics

Volumn 16, Issue 2, 2014, Pages 174-179

  Jennings, Lawrence J ^a,b   George, David ^a   Czech, Juliann ^a   Yu, Min ^a   Joseph, Loren ^c  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION, GENETIC;

EID: 84894106402     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2013.10.007     Document Type: Article

References (44)

1. T.P. Hughes, J. Kaeda, S. Branford, Z. Rudzki, A. Hochhaus, M.L. Hensley, I. Gathmann, A.E. Bolton, I.C. van Hoomissen, J.M. Goldman, J.P. Radich International Randomised Study of Interferon versus STISG (IRIS) Study Group Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 2003 1423 1432
2. B.J. Druker, F. Guilhot, S.G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M.W. Deininger, R.T. Silver, J.M. Goldman, R.M. Stone, F. Cervantes, A. Hochhaus, B.L. Powell, J.L. Gabrilove, P. Rousselot, J. Reiffers, J.J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J.L. Nielsen, J.P. Radich, B. Simonsson, K. Taylor, M. Baccarani, C. So, L. Letvak, R.A. Larson IRIS Investigators Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
3. M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, A. Gratwohl, F. Guilhot, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, D. Niederwieser, R. Silver, R. Hehlmann European LeukemiaNet Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 2006 1809 1820
4. T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N.C. Cross, B.J. Druker, J. Gabert, D. Grimwade, R. Hehlmann, S. Kamel-Reid, J.H. Lipton, J. Longtine, G. Martinelli, G. Saglio, S. Soverini, W. Stock, and J.M. Goldman Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 2006 28 37
5. S. Branford, T.P. Hughes, and Z. Rudzki Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics Br J Haematol 107 1999 587 599
6. T.P. Hughes, A. Hochhaus, S. Branford, M.C. Muller, J.S. Kaeda, L. Foroni, B.J. Druker, F. Guilhot, R.A. Larson, S.G. O'Brien, M.S. Rudoltz, M. Mone, E. Wehrle, V. Modur, J.M. Goldman, J.P. Radich, and IRIS Investigators Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) Blood 116 2010 3758 3765
7. R.D. Press, Z. Love, A.A. Tronnes, R. Yang, T. Tran, S. Mongoue-Tchokote, M. Mori, M.J. Mauro, M.W. Deininger, and B.J. Druker BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML Blood 107 2006 4250 4256
8. T. Zhang, S. Grenier, B. Nwachukwu, C. Wei, J.H. Lipton, S. Kamel-Reid Association for Molecular Pathology Hematopathology Subdivision Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations J Mol Diagn 9 2007 421 430
9. S. Branford, N.C. Cross, A. Hochhaus, J. Radich, G. Saglio, J. Kaeda, J. Goldman, and T. Hughes Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia Leukemia 20 2006 1925 1930
10. S. Branford, L. Fletcher, N.C. Cross, M.C. Muller, A. Hochhaus, D.W. Kim, J.P. Radich, G. Saglio, F. Pane, S. Kamel-Reid, Y.L. Wang, R.D. Press, K. Lynch, Z. Rudzki, J.M. Goldman, and T. Hughes Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials Blood 112 2008 3330 3338
11. H.E. White, P. Matejtschuk, P. Rigsby, J. Gabert, F. Lin, Y. Lynn Wang, S. Branford, M.C. Muller, N. Beaufils, E. Beillard, D. Colomer, D. Dvorakova, H. Ehrencrona, H.G. Goh, H. El Housni, D. Jones, V. Kairisto, S. Kamel-Reid, D.W. Kim, S. Langabeer, E.S. Ma, R.D. Press, G. Romeo, L. Wang, K. Zoi, T. Hughes, G. Saglio, A. Hochhaus, J.M. Goldman, P. Metcalfe, and N.C. Cross Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA Blood 116 2010 e111 e117
12. M.C. Muller, N.C. Cross, P. Erben, T. Schenk, B. Hanfstein, T. Ernst, R. Hehlmann, S. Branford, G. Saglio, and A. Hochhaus Harmonization of molecular monitoring of CML therapy in Europe Leukemia 23 2009 1957 1963
13. M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, F. Cervantes, M. Deininger, A. Gratwohl, F. Guilhot, A. Hochhaus, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, J. Radich, B. Simonsson, R.T. Silver, J. Goldman, R. Hehlmann, and European LeukemiaNet Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 2009 6041 6051
14. D.M. Ross, and S. Branford Minimal residual disease: the advantages of digital over analog polymerase chain reaction Leuk Lymphoma 52 2011 1161 1163
15. N.C. Cross, H.E. White, M.C. Muller, G. Saglio, and A. Hochhaus Standardized definitions of molecular response in chronic myeloid leukemia Leukemia 26 2012 2172 2175
16. F.X. Mahon, D. Rea, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, L. Legros, A. Charbonnier, A. Guerci, B. Varet, G. Etienne, J. Reiffers, P. Rousselot Intergroupe Francais des Leucemies Myeloides Chroniques Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol 11 2010 1029 1035
17. D.M. Ross, S. Branford, J.F. Seymour, A.P. Schwarer, C. Arthur, P.A. Bartley, C. Slader, C. Field, P. Dang, R.J. Filshie, A.K. Mills, A.P. Grigg, J.V. Melo, and T.P. Hughes Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR Leukemia 24 2010 1719 1724
18. O. Benjamini, H. Kantarjian, M.B. Rios, E. Jabbour, S. O'Brien, P. Jain, M. Cardenas-Turanzas, S. Faderl, G. Garcia-Manero, F. Ravandi, G. Borthakur, A. Quintas-Cardama, and J. Cortes Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience Leuk Lymphoma 2013 [Epub ahead of press]
19. N. Thielen, B. van der Holt, J.J. Cornelissen, G.E. Verhoef, T. Gussinklo, B.J. Biemond, S.M. Daenen, W. Deenik, R. van Marwijk Kooy, E. Petersen, W.M. Smit, P.J. Valk, G.J. Ossenkoppele, and J.J. Janssen Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON) Eur J Cancer 49 2013 3242 3246
20. D.M. Ross, S. Branford, J.F. Seymour, A.P. Schwarer, C. Arthur, D.T. Yeung, P. Dang, J.M. Goyne, C. Slader, R.J. Filshie, A.K. Mills, J.V. Melo, D.L. White, A.P. Grigg, and T.P. Hughes Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study Blood 122 2013 515 522
21. H.Y. Yhim, N.R. Lee, E.K. Song, C.Y. Yim, S.Y. Jeon, S. Shin, J.A. Kim, H.S. Kim, E.H. Cho, and J.Y. Kwak Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response Leuk Res 36 2012 689 693
22. N. Takahashi, T. Kyo, Y. Maeda, T. Sugihara, K. Usuki, T. Kawaguchi, N. Usui, S. Okamoto, Y. Ohe, S. Ohtake, K. Kitamura, M. Yamamoto, H. Teshima, T. Motoji, T. Tamaki, K. Sawada, and K. Ohyashiki Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia Haematologica 97 2012 903 906
23. I. Hardan, A. Stanevsky, Y. Volchek, T. Tohami, N. Amariglio, L. Trakhtenbrot, M. Koren-Michowitz, A. Shimoni, and A. Nagler Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia Cytokine 57 2012 290 293
24. D. Marin, A. Bazeos, F.X. Mahon, L. Eliasson, D. Milojkovic, M. Bua, J.F. Apperley, R. Szydlo, R. Desai, K. Kozlowski, C. Paliompeis, V. Latham, L. Foroni, M. Molimard, A. Reid, K. Rezvani, H. de Lavallade, C. Guallar, J. Goldman, and J.S. Khorashad Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib J Clin Oncol 28 2010 2381 2388
25. R.D. Press, C. Galderisi, R. Yang, C. Rempfer, S.G. Willis, M.J. Mauro, B.J. Druker, and M.W. Deininger A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response Clin Cancer Res 13 2007 6136 6143
26. R.D. Press, S.G. Willis, J. Laudadio, M.J. Mauro, and M.W. Deininger Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib Blood 114 2009 2598 2605
27. S. Branford, Z. Rudzki, I. Parkinson, A. Grigg, K. Taylor, J.F. Seymour, S. Durrant, P. Browett, A.P. Schwarer, C. Arthur, J. Catalano, M.F. Leahy, R. Filshie, K. Bradstock, R. Herrmann, D. Joske, K. Lynch, and T. Hughes Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations Blood 104 2004 2926 2932
28. D. George, J. Czech, B. John, M. Yu, and L.J. Jennings Detection and quantification of chimerism by droplet digital PCR Chimerism 4 2013 102 108
29. S. Weaver, S. Dube, A. Mir, J. Qin, G. Sun, R. Ramakrishnan, R.C. Jones, and K.J. Livak Taking qPCR to a higher level: analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution Methods 50 2010 271 276
30. B.J. Hindson, K.D. Ness, D.A. Masquelier, P. Belgrader, N.J. Heredia, A.J. Makarewicz, and et al High-throughput droplet digital PCR system for absolute quantitation of DNA copy number Anal Chem 83 2011 8604 8610
31. F.M. Lun, N.B. Tsui, K.C. Chan, T.Y. Leung, T.K. Lau, P. Charoenkwan, K.C. Chow, W.Y. Lo, C. Wanapirak, T. Sanguansermsri, C.R. Cantor, R.W. Chiu, and Y.M. Lo Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma Proc Natl Acad Sci U S A 105 2008 19920 19925
32. A.N. Barrett, T.C. McDonnell, K.C. Chan, and L.S. Chitty Digital PCR analysis of maternal plasma for noninvasive detection of sickle cell anemia Clin Chem 58 2012 1026 1032
33. Y.M. Lo, F.M. Lun, K.C. Chan, N.B. Tsui, K.C. Chong, T.K. Lau, T.Y. Leung, B.C. Zee, C.R. Cantor, and R.W. Chiu Digital PCR for the molecular detection of fetal chromosomal aneuploidy Proc Natl Acad Sci U S A 104 2007 13116 13121
34. C.M. Hindson, J.R. Chevillet, H.A. Briggs, E.N. Gallichotte, I.K. Ruf, B.J. Hindson, R.L. Vessella, and M. Tewari Absolute quantification by droplet digital PCR versus analog real-time PCR Nat Methods 10 2013 1003 1005
35. N. Farago, A.K. Kocsis, S. Lovas, G. Molnar, E. Boldog, M. Rozsa, V. Szemenyei, E. Vamos, L.I. Nagy, G. Tamas, and L.G. Puskas Digital PCR to determine the number of transcripts from single neurons after patch-clamp recording Biotechniques 54 2013 327 336
36. P.J. Sykes, S.H. Neoh, M.J. Brisco, E. Hughes, J. Condon, and A.A. Morley Quantitation of targets for PCR by use of limiting dilution Biotechniques 13 1992 444 449
37. L.B. Pinheiro, V.A. Coleman, C.M. Hindson, J. Herrmann, B.J. Hindson, S. Bhat, and K.R. Emslie Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification Anal Chem 84 2012 1003 1011
38. L.J. Jennings, F.A. Smith, K.C. Halling, D.L. Persons, S. Kamel-Reid, and Molecular Oncology Resource Committee of the College of American Pathologists Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease Arch Pathol Lab Med 136 2012 33 40
39. R.D. Press, S. Kamel-Reid, and D. Ang BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia J Mol Diagn 15 2013 565 576
40. J.T. Brown, W. Laosinchai-Wolf, J.B. Hedges, C.D. Watt, V.M. Van Deerlin, L. Fletcher, S. Branford, and E. Labourier Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale Blood Cancer J 1 2011 e13
41. H.G. Goh, M. Lin, T. Fukushima, G. Saglio, D. Kim, S.Y. Choi, S.H. Kim, J. Lee, Y.S. Lee, S.M. Oh, and D.W. Kim Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay Leuk Lymphoma 52 2011 896 904
42. P.A. Bartley, M.H. Martin-Harris, B.J. Budgen, D.M. Ross, and A.A. Morley Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia Br J Haematol 149 2010 231 236
43. M. Sobrinho-Simoes, V. Wilczek, J. Score, N.C. Cross, J.F. Apperley, and J.V. Melo In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib Blood 116 2010 1329 1335
44. E. Mattarucchi, O. Spinelli, A. Rambaldi, F. Pasquali, F. Lo Curto, L. Campiotti, and G. Porta Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis J Mol Diagn 11 2009 482 487